Marotte, Hubert <br/><br/>
Circulating tumour necrosis factor-alpha bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical response.  [electronic resource] 

 -  Arthritis research & therapy  2005 
 - R149-55 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article 
<br/><br/><label>ISSN: </label>1478-6362 
<br/><br/><label>Standard No.: </label>10.1186/ar1465  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antibodies, Monoclonal--administration & dosage<br/>Arthritis, Rheumatoid--blood<br/>Autoimmune Diseases--blood<br/>Biological Assay<br/>Cells, Cultured--drug effects<br/>Female<br/>Gene Expression Regulation--drug effects<br/>Glycoproteins--biosynthesis<br/>Humans<br/>Individuality<br/>Infliximab<br/>Infusions, Intravenous<br/>Interleukin-6--biosynthesis<br/>Male<br/>Middle Aged<br/>Osteoprotegerin<br/>Receptors, Cytoplasmic and Nuclear--biosynthesis<br/>Receptors, Tumor Necrosis Factor--biosynthesis<br/>Synovial Membrane--drug effects<br/>Treatment Outcome<br/>Tumor Necrosis Factor-alpha--analysis